Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZP-507 versus Xyrem bioequivalence and food-effect crossover study in healthy adults
NL-OMON45490Withdrawn
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sodium oxybate in narcolepsy and cataplexy (3 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Bioequivalence of JZP-507 versus Xyrem under fasting conditions. Planned start Jan 2017; status: withdrawn.
02
Drugs
sodium oxybate
03
Conditions
narcolepsycataplexy
Beyond the preview
Go deeper on NL-OMON45490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45490.